JUL 11, 2020 1:07 PM PDT

New drug combo could improve immunotherapy for SCCOHT ovarian cancer

Research published recently in PLOS ONE reports on SP-2577, a drug that could help girls and young women plagued with a type of ovarian cancer known as Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT). According to researcher Dr. Jeffrey Trent, who has been working on this topic at the Translational Genomics Research Institute (TGen) for years, SP-2577 could tap the immune system to help combat SCCOHT.

In the study, The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer, the researcher team proposes a two-fold attack, combining SP-2577, or Seclidemstat, with another immunotherapeutic compound. 

"Immunotherapy is the future of cancer treatment. Our combination of drugs should promote an immune response in an ovarian cancer that usually does not respond well to immunotherapies," said lead author Dr. Raffaella Soldi, a TGen Research Associate Professor. "One drug opens a biological gate, while the other drug helps push immune cells through the gate to attack the cancer."

SP-2577 works by inhibiting a protein called LSD1, which is known to play a role in SCCOHT ovarian cancer, among other cancer types. 

"We suggest in this paper that LSD1 inhibition should improve the immune-therapy response in these tumors. This treatment is exquisitely dependent on the mutation found by Dr. Trent and his group. Without that mutation, this treatment would not work," commented senior author Dr. Sunil Sharma, TGen Deputy Director of Clinical Sciences. 

Dr. Sharma is referring to a previous discovery that a single mutation in a gene called SMARCA4 triggered SCCOHT. Interestingly, this gene had been shown before to be associated with lung, brain, and pancreatic cancer.  "The correlation between mutations in SMARCA4 and the development of SCCOHT is simply unmistakable," explained Dr. Trent in reference to this finding.

The SP-2577 and Pembrolizumab combination is soon to be tested in clinical trials for patients with SCCOHT ovarian cancer. 

Sources: PLOS ONE, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
APR 12, 2021
Cancer
Using antibodies to treat melanoma
APR 12, 2021
Using antibodies to treat melanoma
New research presented at the American Association of Cancer Research (AACR) virtual annual meeting this week from the Y ...
APR 15, 2021
Cancer
What should breast cancer treatment in older women look like?
APR 15, 2021
What should breast cancer treatment in older women look like?
A new study published in JAMA Network Open by researchers at UPMC Hillman Cancer Center and the University of Pittsburgh ...
MAY 26, 2021
Genetics & Genomics
Connecting Bacterial Genes to Human Disease
MAY 26, 2021
Connecting Bacterial Genes to Human Disease
This kind of research gets us closer to using fecal samples to get a snapshot of the microbiome, and make disease risk p ...
JUN 07, 2021
Cell & Molecular Biology
Overcoming Challenges to Detect Apoptosis in 3D Cell Structures
JUN 07, 2021
Overcoming Challenges to Detect Apoptosis in 3D Cell Structures
Researchers are increasingly relying on cells grown in three-dimensional (3D) structures to help answer their research q ...
JUN 08, 2021
Immunology
Fueling the Immune System's Killers
JUN 08, 2021
Fueling the Immune System's Killers
There’s a group of “killers” protecting your body against infections and eliminating potentially cance ...
JUN 11, 2021
Cell & Molecular Biology
Bad Fat in the Tumor Microenvironment May Disrupt Killer T Cells
JUN 11, 2021
Bad Fat in the Tumor Microenvironment May Disrupt Killer T Cells
The immune system can detect and destroy pathogenic and cancerous cells, but sometimes those dangerous cells can evade t ...
Loading Comments...